Smart Cancer Drug RK-251 Activates Only in Cancer Cells, Offering Targeted Alternative to Chemotherapy
核心洞察
Researchers from IASST and IIT-Guwahati developed RK-251 (搜索), a "smart" prodrug that activates primarily inside cancer cells rather than harming healthy tissue.
RK-251 (搜索) uses elevated reactive oxygen species (ROS) in cancer cells to trigger release of NBDHEX, a potent GSTP1 (搜索) inhibitor that blocks proteins cancer cells need to survive.
Preclinical studies showed strong activity against aggressive triple-negative breast cancer (搜索) cells with much less effect on healthy cells, and no obvious toxicity in zebrafish embryos.
A new "smart" cancer drug designed to switch on and work only inside cancer cells could replace traditional chemotherapy, which in many cases also harms healthy cells. Collaborative research led by Dr. Asis Bala from the Institute of Advanced Study in Science and Technology (IASST) (搜索), an Autonomous Institute under the Department of Science & Technology (Govt. of India), and Dr. K.P. Bhabak from the Indian Institute of Technology-Guwahati (搜索) has developed the candidate drug, called RK-251 (搜索).
Cancer treatment often damages healthy cells along with cancer cells, causing significant associated adverse effects and side effects. This has created a need for targeted therapies that remain inactive in normal tissues while traveling through the body and become activated specifically at tumor sites. RK-251 (搜索) is designed to activate primarily in cancer cells and does not harm healthy cells.
Mechanism of Action
Cancer cells often produce high levels of reactive oxygen species (ROS), which are harmful molecules. When RK-251 (搜索) enters a cancer cell, the high ROS levels trigger the drug's activation, releasing a powerful anticancer compound called "NBDHEX." This compound blocks target proteins that many cancer cells use to survive and resist treatment.
Many cancer cells produce high amounts of an enzyme called GSTP1 (搜索), which can help cancer cells survive by neutralising certain anticancer drugs. Blocking the GSTP1 enzyme could potentially make cancer cells more vulnerable. Currently, an experimental drug called NBDHEX is a potent GSTP1 inhibitor; however, it does not dissolve well in water and is poorly absorbed by the body, making it difficult to use effectively as a medicine.
Researchers from IASST and IIT-Guwahati have turned NBDHEX into the RK-251 (搜索) prodrug — an inactive form of a drug designed to become active under specific conditions. Cancer cells have higher levels of ROS, which are chemically reactive molecules produced during cellular processes. RK-251 is designed so that these higher ROS levels can act as a chemical trigger. Once it enters a cancer cell — an ROS-rich environment — the ROS activates RK-251, causing the molecule to break apart and release NBDHEX. The result is inhibition of GSTP1 (搜索).
Theranostic Capabilities
RK-251 (搜索) also carries a fluorescent molecule called QCy7. When the prodrug is activated and releases its components, it produces near-infrared fluorescence. Under these conditions, NBDHEX is released, inhibiting GSTP1 (搜索) and attacking cancer cells, while the fluorescence allows researchers to see that the drug has been activated. This is called a theranostic approach, which combines therapy and diagnostics or imaging in one system.
Preclinical Findings
In preclinical studies, RK-251 (搜索) showed strong activity against aggressive triple-negative breast cancer (搜索) cells, with much less effect on healthy cells. The behavioral study of the developed candidate drug in zebrafish embryos (Danio rerio) also showed no obvious signs of toxicity and exhibited the desired fluorescence in the presence of reactive oxygen species (ROS), suggesting the drug may be safe for further research and validation.
Researchers stressed that while the findings are promising, more studies are needed before the technology can be tested in patients. The work is published in ACS-Journal of Medicinal Chemistry.